NCT01737619 - PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

April 3, 2013

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions

Endometrial Clear Cell AdenocarcinomaEndometrial Mixed AdenocarcinomaEndometrial Serous AdenocarcinomaGrade 3 Endometrial Endometrioid AdenocarcinomaMalignant Mixed Mesodermal (Mullerian) Tumor

Interventions

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Indocyanine Green Solution

Given via superficial and deep cervical injection

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Lymph Node Mapping

Undergo lymph node mapping

PROCEDURE

Lymphadenectomy

Undergo full lymphadenectomy

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (7)

77030

M D Anderson Cancer Center, Houston

77054

The Woman's Hospital of Texas, Houston

77058

MD Anderson Regional Care Center-Bay Area, Nassau Bay

77094

MD Anderson Regional Care Center-Katy, Houston

77384

MD Anderson Regional Care Center-The Woodlands, The Woodlands

77478

MD Anderson Regional Care Center-Sugar Land, Sugar Land

77026-1967

Lyndon Baines Johnson General Hospital, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER